YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1.

Ookura, Miyuki; Fujii, Tatsuya; Yagi, Hideki; Ogawa, Takuya; Kishi, Shinji; Hosono, Naoko; Shigemi, Hiroko; Yamauchi, Takahiro; Ueda, Takanori; Yoshida, Akira

YM155 exerts potent cytotoxic activity against quiescent (G₀/G₁) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1.

Ookura, Miyuki; Fujii, Tatsuya; Yagi, Hideki; Ogawa, Takuya; Kishi, Shinji; Hosono, Naoko; Shigemi, Hiroko; Yamauchi, Takahiro; Ueda, Takanori; Yoshida, Akira.

Afiliação

Ookura M; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Fujii T; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Yagi H; Department of Pharmaceutical Sciences, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan.
Ogawa T; Department of Pharmaceutical Sciences, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan.
Kishi S; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Hosono N; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Shigemi H; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Yamauchi T; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Ueda T; Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Yoshida A; Department of Hematology, International University of Health and Welfare Hospital, Iguchi, Nasushiobara, Tochigi, 329-2763, Japan.